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Aim: To screen for the anti-mycobacterial activity of Canthium crassum and Sterculia quinqueloba 
using two mycobacteria species the Mycobacteria madagascariense and Mycobacteria 
indicuspranii. 
Study Design: In vitro assay of anti-mycobacterial assay was done using 96-well micro-dilution 
method. 
Place and Duration of Study: School of Life Science and Bioengineering, Nelson Mandela African 
Institution of Science and Technology, Arusha, Tanzania, from April 2014 to June 2014.   
Methodology: 96-well-microtitre serial micro-dilution method was used to determine anti-











mycobacteria activity to plant extracts. 
Results: All extracts exhibited anti-mycobacterial activity to both mycobacteria tested. The 
minimum inhibition concentration (MIC) ranged from 0.39 – 12.5 mg/mL, with ethyl acetate leaf 
extract of S. quinqueloba being the most active extracts with MIC value of 0.39 mg/mL against 
Mycobacteria madagascariense (MM) and 0.78 mg/mL against Mycobacteria indicuspranii (MIP). 
Petroleum ether and ethyl acetate leaf extract of C. crassum also gave MIC value of 0.78 mg/mL 
against MM and MIP.  
Conclusion: Findings from the present study showed that both plants exhibited activity against 
mycobacterium species tested. These plants may therefore serve as a source for new ant-








According to the World Health Organization 
(WHO), tuberculosis (TB) caused by micro-
organism of genus Mycobacterium is a second to 
HIV/AIDS as the greatest killer worldwide and 
resulted in deaths of approximately 1.3 million 
patients in 2012 alone. It is a leading killer of 
people living with HIV and over 95% of the 
deaths occur in the developing countries [1]. The 
most available treatment requires a long lasting 
(at least six months) multi-drug scheme which 
causes difficulties to patients. Similarly, the 
recorded multi-drug resistant (MDR) and 
extensively-drug resistant (XDR) strains of 
Mycobacterium tuberculosis [2], increases the 
hurtful to a patient’s health due to repeated use 
of the drugs and increased levels of multi-drug 
toxicity to the patient’s body [3]. Recent records 
showed that in 2012 alone, about 450,000 
people developed multidrug-resistant 
tuberculosis; most of them were from developing 
countries [1]. 
 
Africa which is the poorest continent in the world, 
faces the worst tuberculosis epidemic ever since 
time immemorial [4]. It is a home of 
approximately 13% of the world population but 
faces approximately 30% of the global burden of 
all the reported TB cases [4,5]. This is also trickle 
down to many poorest African countries like East 
African countries. For instance, Tanzania is 
among the 22 countries with highTB-burden in 
the world with approximately more than 70,000 
new cases annually and in 2007 alone with 
approximately 292 incidences per 100,000 
population [6,7]. This growth of tuberculosis 
cases in Tanzania and other parts in Africa is 
attributed by many factors including ineffective 
treatment programme for TB control, HIV 
epidemic and continued transmission due to low 
level of population precaution [6,8,9], this factors 
have also contributed much into the emergence 
and spread of MDR and XDR strains [7,8]. 
This emergence and spread of MDR and XDR 
strains and the recorded high human death rate 
due to TB infections, necessitate the discovery of 
new classes of antibacterial and compounds that 
can inhibit the growth of these micro-organisms 
[10,11]. It is also important to ensure that the 
discovery process of the new anti-TB agents is 
seriously undertaken, since most of the affected 
individuals in developing countries like Tanzania 
are in productive age class, thus put 
development activities to these countries in 
jeopardy [12]. Medicinal plants offer a great hope 
for developing alternative medicines for the 
treatment of TB due to their  phytochemical 
diversity [2,3]. Since ancient times, several plants 
have been used locally to treat various ailments 
including TB-related diseases [13,14], these 
include plants from East Africa [15,16]. The 
genus Sterculia and Canthium are well 
represented in East Africa and known to 
comprise antimicrobial activities; some of which 
have demonstrated anti-TB activity. For instance, 
Babalola et al. [17] and Yang et al. [18] observed 
that Sterculia setigera and Canthium horridum 
respectively had promising antimicrobial activity 
with S. setigera exhibiting promising anti-TB 
activity.  
 
Sterculia quinqueloba (Garcke) K. Schum 
(Malvaceae) and Canthium crassum Hiern 
(Rubiaceae) are tree plant species found in 
eastern and southern Africa countries and which 
are medicinally used to some of the communities 
to treat various ailments including diarrhea, skin 
diseases, earache and venereal diseases 
[19,20]. The anti-bacterial and anti-fungal 
activities of extracts from dried leaves, stem and 
root barks of these plants against common 
microbes such as Escherichia coli, 











pneumonia, Staphylococcus aureus, Vibrio 
cholera, Shigella flexineri, Proteus vulgaris, 
Salmonella typhi, Klebsiella oxytoca, 
Cryptococcus neofarmans and Candidas 
albicans have been reported [21]. In this respect, 
the current study was undertaken to evaluate the 
anti- mycobacterium activity of extracts from the 
two plants, the S. quinqueloba and C. crassum. 
 
2. MATERIALS AND METHODS 
 
2.1 Solvents, Reagents and Growth Media 
 
Methanol was bought from Fluka Chemie GmbH 
(Sigma-Aldrich®, Zwijndrecht, Netherlands) and 
Dimethyl sulfoxide (DMSO) was purchased from 
RFCL Limited, Hayana, India whereas petroleum 
ether and ethyl acetate were purchased from 
Loba Chemie Pvt Ltd, Mumbai, INDIA. Middle 
Brook 7H9 Broth was purchased from Sigma-
Aldrich® Co whereas standard TB drugs; 
Isoniazid, Rifampicin and kanamycin were 
supplied by Macleods Pharmaceuticals LTD- 
Atlanta Arcade, Marol Church Road, Andheri (E), 
Mumbai-400-059, India.  
 
2.2 Collection of Plant Materials and 
Extraction 
 
Mr. Haji Seleman, a botanist from University of 
Dar es Salaam identified leave, stem and root 
barks of S. quinqueloba and C. crassum which 
were collected inKigoma region atGombe 
National Park. The specimens were kept at 
Nelson Mandela Africa Institution of Science and 
Technology (NM-AIST) with voucher specimen 
numbers 2141 and 2142 for S. quinqueloba and 
C. crassum respectively. The samples were dried 
under the shade and then powdered into the fine 
particles. The powdered leave of S. quinqueloba 
and C. crassum, stem bark of S. quinqueloba 
and root bark of C. crassum were sequentially 
extracted through maceration using petroleum 
ether, ethyl acetate and methanol for 24 hours. 
The extracts were then filtered through muslin 
cloth on a plug of glass wool in a glass column 
and solvents were separated from extract using 
rotary evaporator and pure extract were stored in 
a refrigerator at 4℃. 
 
2.3 Sub-culturing of the Mycobacteria 
Strains 
 
The S. quinqueloba and C. crassum extracts 
were evaluated against Mycobacteria 
madagascariense (DSM 44641) and 
Mycobacteria indicuspranii (DSM 45239) 
supplied by DSMZ - The Germany Resource 
Centre for Biological Materials, Braunschweig, 
Germany. These strains were used as a marker 
for determination of potential anti-tuberculosis 
efficacy of extracts. The sub-culturing activity 
was conducted as explained by Mwembela et al. 
[22], by simply sub-culturing the strains in liquid 
media and Middle brook 7H9 broth base. 0.64g 
of Middlebrook 7H9 broth base was suspended 
in 115 mL of distilled water in two separate 
Scotch bottles of 250 ml each. Thereafter, 0.5 ml 
of glycerol (AR) was added into each scotch 
bottle and the mixture was thoroughly shaken to 
dissolve the broth completely and then 
autoclaved at 121℃ for 15 minutes. Thereafter, 
the mixture was left to cool to 31 and 37℃ under 
lamina flow before being inoculated with 
Mycobacteria madagascariense (MM) and 
Mycobacteria indicuspranii (MIP) respectively. 
Later on, MM and MIP were incubated at 31℃ 
and 37℃ respectively. 
 
2.4 Determination of Minimum Inhibitory 
Concentration (MIC) 
 
Minimum inhibitory concentrations (MICs) of the 
extracts against two standard Mycobacterium 
were determined by micro dilution method [23] 
done in triplicate using 96 well microtitre plates. 
Firstly the plates were loaded with 50 μL of the 
broth media followed by addition of 50 μL of the 
extract (100 mg/mL) into first wells of each row 
tested to make a total volume of 100 µL in each 
first wells. After thorough mixing of first row of 
each plate, 50 µL were taken from each of the 
first row wells and added into the next row wells. 
This process was repeated down the columns to 
the last wells at the bottom at which 50 µL taken 
from the last rows of each column were 
discarded. Thereafter, 50 µL of approximately 
0.5 MacFarhland standard turbidity of both MM’s 
and MIP’s suspension were added into each well 
to make the final of 100 µL in each well. 
Additionally, the rows containing DMSO were 
used as negative control and the rows with broth 
and bacteria only were used to monitor bacterial 
growth whereas the rows containing isoniazid, 
rifampicin and kanamycin were used as a 
standard positive control drugs. Thereafter, the 
plates were incubated at 32℃ and 37℃ for MM 
and MIP respectively for 24 hours. The minimum 
inhibitory concentrations were then determined 
by addition of 20 µL of 0.02% p-
iodonitrotetrazolium (INT) chloride dye in each 
well followed by incubation for 1 hour at 32℃ and 











indication of mycobacterium growth and the rows 
with no color change marks the activity of 




The minimum inhibition concentration (MIC) of S. 
quinqueloba and C. crassum extracts were 
evaluated for their anti-mycobacterial activity 
against two very fast growing Mycobacteria 
strains which are Mycobacteria 
madagascariense (MM) and Mycobacteria 
indicuspranii (MIP). Results observed are 
summarized in Table 1. The anti-MIP and anti-
MM activity of the both plants extracts displayed 
different MIC range values, 0.39 mg/mL – 12 
mg/mL for MM and 0.78 mg/mL – 12.5 mg/mL for 
MIP. All leaf extracts of the two plants and ethyl 
acetate root bark extracts of C. crassum 
exhibited a higher activity MIC range of 0.39 – 
6.25 mg/mL against the tested strains when 
compared with isoniazid which is the first line 
anti-mycobacterial drug which gave MIC value of 
12.5 mg/mL against both strains tested. Previous 
studies had reported the observed mycobacterial 
resistance cases against isoniazid [24,25] and 
indeed they are in line with the current results. 
 
The trend of activity displayed by both plants 
indicated thatethyl acetate leaf extracts of S. 
quinqueloba hada higher activity compared to 
other plant parts (MIC value range of 0.39 – 0.78 
mg/ml), followed by ethyl acetate leaf extracts of 
C. crassum (0.78 mg/mL), methanolic leaf 
extracts of S. quinqueloba and petroleum ether 
leaf extracts of C. crassum (0.78 mg/mL – 1.56 
mg/mL), petroleum ether leaf extracts of S. 
quinqueloba (1.56 mg/mL) and methanolic leaf 
extracts of C. crassum (1.56 mg/mL – 3.12 
mg/mL). Save for ethyl acetate root bark extracts 
of C. crassum which had MIC value of 0.78 
mg/mL against MM, all other stem and root bark 
extracts of both plants against the 2 strains 
tested gave activity that ranged from 3.12 – 12.5 




There are many researches on anti-
mycobacterial activities of plants but based on 
our investigation, there was no any published 
study of anti-mycobacterial evaluation on S. 
quinqueloba and C. crassum. Results from the 
present study indicated that S. quinqueloba and 
C. crassum have anti-mycobacterial activity 
against both strains tested with leaf extracts 
being most active compared to other parts. The 
ethyl acetate leaf extracts of S. quinqueloba 
exhibited a higher activity range than other parts 
indicating the anti-mycobacterial potential of 
middle polar compounds (secondary metabolites) 
existing in the leaves of S. quinqueloba. Although 
Babalola et al. [17] performed ant-
mycobacterium test using only leaves extract of 
S. setigera against virulent Mycobacterium 
tuberculosis (H37Rv) strain, it is evident that, 
leaves extracts of the both plants have promising 
therapeutic potency against mycobacterium 
strains, with middle polar compounds being 
significantly active comparable to other extracts 
(non-polar and polar extracts). Yang et al. [18] on 
the other hand had observed that, the stem 
extract of C. horridium had remarkable activity 
against various bacteria strains. Although C. 
horridium extracts were not tested for anti-
mycobacterial activity, the syringic acid and 
coumarins isolated from this plant had being 
identified to possess ant mycobacterial activity 
[26,27]. Generally genus Sterculia and Canthium 
have shown a number of anti-bacterial activities 
which gave an indication that, some of these 
species might have anti-mycobacterial potency 
particularly on the aerial parts [28]. The leaf 
extracts of the both plants, were very active than 
other parts tested, and they had activity 16 times 
higher than isoniazid, the first line anti-TB drug.  
 
Like wise, some extracts from other parts of the 
two plants tested had the activity higher than 
isoniazid (activity range 0.78 – 6.25 mg/ml). 
These results is an indication that the two plants 
have a number of secondary metabolites that 
can be worth further researched for the effort to 
discover new classes of compounds responsible 
for ant-mycobacterial activity. This effort should 
be intensified because despite the intense hard 
work on the ant-mycobacterial screening from 
plants, none of the current ant-TB agents from 
plant origin are used as first or even second line 
drugs, while TB infections is still remains as one 
of the global development and health problems 
[3,27]. The emergence and spread of MDR and 
XDR strains further expected to destabilize the 
very effort undertaken to control this disease in 
many parts of the world including developing 
country like Tanzania. Among other things this 
country (Tanzania) is limited to funding, experts, 
facilities, medication supplies and laboratory 
capabilities which due to the current existence of 
MDR and XDR strains cases, fighting against    
TB become even more serious problem to 













Table 1. Antimycobacterial Activity of Sterculia quinqueloba and Canthium crassum  
against MM and MIP 
 
Minimum inhibitory concentration (MIC) in mg/Ml 
Plant extracts Mycobacteria madagascariense (MM) Mycobacteria indicuspranii (MIP) 
SQLP 1.56 1.56 
SQLE 0.39 0.78 
SQLM 0.78 1.56 
SQSP 12.5 3.12 
SQSE 3.12 3.12 
SQSM 12.5 6.25 
CCLP 1.56 0.78 
CCLE 0.78 0.78 
CCLM 1.56 3.12 
CCRP 3.12 6.25 
CCRE 0.78 12.5 
CCRM 3.12 12.5 
Isoniazid 12.5 12.5 
Rifampicin 0.19 0.19 
DMSO 12.5 12.5 
Key: SQLP= S. quinqueloba leaf PE extract, SQLE= S. quinqueloba leaf EtOAc extract, SQLM= S. quinqueloba 
MeOH leaf extract, SQSP =S. quinqueloba stem PE extract, SQSE= S. quinqueloba stem EtOAc extract, SQSM= 
S. quinqueloba stem MeOH extract, CCLP= C. crassum leaf PE extract, CCLE= C. crassum leaf EtOAc extract, 
CCLM= C. crassum leaf MeOH extract, CCRP= C. crassum root PE extract, CCRE= C. crassum root EtOAc 
extract, CCRM= C. crassum root MeOH extract 
 
It is therefore our interest to report the anti-
mycobacterial activity of these two plants which 
are medicinally used to treat various ailments in 
Tanzania including bacterial infections. The anti-
mycobacterial activity observed from these two 
plants might be due tothe presence of alkaloids, 
flavonoids, tannins, saponins, long chain fatty 
acid, quinone, tarpenoids, phenols and steroids 
reported to exist in many Sterculia and Canthium 
species [17, 29-32], which according to Celis et 
al. [33], Meenakshi et al. [34] and Abd-Alrahman 
et al. [35] the mentioned compounds had shown 
the antimicrobial activity. Likewise, Brine shrimp 
lethality test which is used as preliminary test of 
extract cytotoxicity conducted by Wilson et al. 
[21] indicated that, ethyl acetate, petroleum ether 
and methanolic leaf extracts of the two plants are 
not toxic to brine shrimp cell. In this regard,it was 
regarded that, the no toxicity to brine shrimp cell 
observed is a good and promising indication that, 
the compounds available in the mentioned 
extracts might be not toxic to human and/or give 
more chances for easily addressing the toxicity 





Sterculia quinqueloba and Canthium crassum 
extracts have shown anti-mycobacterial activity 
with leaf extracts being more active than other 
parts. All leaf extracts showed a higher activity 
than first line anti-mycobacterial drug and the 
isoniazid for at least 16 times. Therefore, leaf 
extracts may be a good source of anti-
mycobacterial compounds worth further 
development. It is also recommended that, 
further toxicity study is needed to verify the 
safety of these two plants since the preliminary 
toxicity study conducted on the leaf extracts 
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